BT
The startup develops orally active therapeutics targeting the mitochondrial apoptosis pathway to enhance cancer treatment efficacy. By utilizing insights from conformationally dynamic protein drivers and structure-based drug design, the company aims to provide lasting therapeutic options for cancer patients.
Updated 20 months ago
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AMSH
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops orally active therapeutics targeting the mitochondrial apoptosis pathway to enhance cancer treatment efficacy. By utilizing insights from conformationally dynamic protein drivers and structure-based drug design, the company aims to provide lasting therapeutic options for cancer patients.